NBIX · Neurocrine Biosciences Inc
$180.81
-2.03 (-1.11%)
At close · Jul 29
Market Cap
$18.18B
Shares
100.55M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.86B
+21.4%
FY2025
Net Income
$478.6M
+40.2%
FY2025
Gross Margin
98.18%
-0.4pp
FY2025
Operating Margin
21.64%
-2.6pp
FY2025
Diluted EPS
$4.67
+41.9%
FY2025
Operating Cash Flow
$782.7M
+31.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.7B – $2.8B | $3.1B | $2.86BG | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788.1M | $451.2M | $161.63M | $15M | $19.77M | $0 | $2.92M | $53.14M | $77.41M | $33.5M | $2.95M | |
| — | $56.7M | $52.1M | $34M | $39.7M | $23.2M | $14.3M | $10.1M | — | $4.89M | $1.25M | $0 | $0 | — | — | — | — | — | — | |
| — | $3.05B | $2.81B | $2.32B | $1.85B | $1.47B | $1.12B | $1.04B | — | $446.31M | $160.37M | $15M | $19.77M | — | — | — | — | — | — | |
| — | — | 98.18% | 98.56% | 97.9% | 98.44% | 98.74% | 99.03% | — | 98.92% | 99.22% | 100% | 100% | — | — | — | — | — | — | |
| — | $1.05B | $1.02B | $731.1M | $565M | $463.8M | $328.1M | $275M | — | $160.52M | $121.83M | $94.29M | $81.49M | $46.43M | $39.25M | $37.16M | $30.95M | $31.15M | $33.72M | |
| — | $84.18M | — | — | — | — | — | — | — | — | — | $68.08M | $32.48M | $17.99M | $13.35M | $13.44M | $12.46M | $13.27M | $14.36M | |
| — | $1.2B | $1.16B | $1.01B | $887.6M | $752.7M | $583.3M | $433.3M | $354.1M | $248.9M | $169.91M | $68.08M | $32.48M | — | — | — | — | — | — | |
| — | — | $4.1M | $3.6M | $3.5M | $500K | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $4.02M | $2.4M | $1.45M | $1.01M | $827K | $671K | $657K | $694K | $1.44M | $3.18M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $2.56M | |
| — | — | — | — | — | — | $1.03B | $882.9M | $715.8M | $414.4M | $292.99M | $162.37M | $113.97M | $64.41M | $52.6M | $51.69M | $43.49M | $47.22M | $56.62M | |
| — | $2.31B | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B | $882.9M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $788.9M | $619.1M | $570.5M | $250.9M | $249M | $102.5M | $163M | $72.3M | $36.8M | -$131.36M | -$147.37M | -$94.2M | -$64.41M | -$49.68M | $1.45M | $33.92M | -$13.72M | -$53.67M | |
| — | — | 21.64% | 24.22% | 13.3% | 16.73% | 9.04% | 15.58% | 9.17% | 8.16% | -81.27% | -982.48% | -476.51% | — | -1701.88% | 2.72% | 43.82% | -40.96% | -1817.47% | |
| — | — | — | — | — | — | — | — | — | $40.82M | -$128.96M | -$145.92M | -$93.19M | -$63.58M | -$49.01M | $2.11M | $34.62M | -$12.29M | -$50.49M | |
| — | $4.6M | — | — | $4.6M | $7.1M | $25.8M | $32.8M | $32M | $30.5M | $19.52M | $0 | $0 | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $2.84M | $1.93M | $629K | $400K | $489K | $435K | $397K | — | |
| — | $148.6M | $86.3M | -$84.5M | $81.2M | -$35.1M | -$1.1M | -$56.3M | -$25.8M | -$15M | -$11.18M | $6.28M | $5.27M | $3.87M | $3.59M | $3.58M | $3.65M | $5.75M | $2.63M | |
| — | $937.5M | $705.4M | $486M | $332.1M | $213.9M | $101.4M | $106.7M | $46.5M | $21.8M | -$142.54M | -$141.09M | — | — | — | — | — | — | — | |
| — | $268.9M | $226.8M | $144.7M | $82.4M | $59.4M | $11.8M | -$300.6M | $9.5M | $700K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | |
| — | $668.6M | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M | $37M | $21.1M | -$142.54M | -$141.09M | -$88.93M | -$60.54M | -$46.09M | $5.03M | $37.57M | -$7.97M | -$51.04M | |
| — | — | 16.73% | 14.49% | 13.23% | 10.38% | 7.9% | 38.94% | 4.69% | 4.68% | -88.19% | -940.6% | -449.84% | — | -1578.97% | 9.46% | 48.53% | -23.78% | -1728.34% | |
| — | $668.6M | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $660M | $485.9M | $340.1M | $264.6M | $148.3M | $86.1M | $407.7M | $40.4M | $21M | -$144.07M | -$140.43M | -$89.63M | -$60.82M | -$46.08M | $5.11M | $37.53M | -$9.23M | -$48.26M | |
| USD/shares | — | — | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | -$1.62 | -$1.63 | -$1.05 | -$0.81 | -$0.69 | $0.08 | $0.68 | -$0.15 | -$1.30 |
| USD/shares | — | — | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | -$1.62 | -$1.63 | -$1.05 | -$0.81 | -$0.69 | $0.08 | $0.67 | -$0.15 | -$1.30 |
| shares | — | — | 99.5M | 100.4M | 97.7M | 95.8M | 94.6M | 93.1M | 91.6M | 90.2M | 88.09M | 86.71M | 84.5M | 74.58M | 66.99M | 65.62M | 55.18M | 52.82M | 39.14M |
| shares | — | — | 102.5M | 103.7M | 101M | 98.9M | 97.9M | 97.8M | 95.7M | 95.4M | 88.09M | 86.71M | 84.5M | 74.58M | 66.99M | 66.95M | 56.35M | 52.82M | 39.14M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2025: $467.7M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.71×
EV/EBIT
—
Peer median 19.44×
P/E (TTM)
27.81×
Peer median 25.20×
Peer medians compare against the 21 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $2,860,500,000 | $2,355,300,000 | $1,887,100,000 | $1,488,700,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $2,833,900,000 | $2,330,600,000 | $1,860,600,000 | $1,440,900,000 | $1,090,100,000 | $994,100,000 | $752,900,000 | $409,600,000 |
| Collaboration Revenue | $26,600,000 | $24,700,000 | $26,500,000 | $47,800,000 | $43,400,000 | $51,800,000 | $35,200,000 | $41,600,000 |
| INGREZZA | — | — | — | $1,400,000,000 | — | — | — | — |
Key facts
CIK
914475
CUSIP
64125C109
13F (30d)
233 filings
206 filers
Visit website
Investor relations